Clinical trial
Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon
NCT00082719 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- January 31, 2015
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bladder cancer, urethral cancer